Internal Med

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Brennan BP et al. - Open-label study, duloxetine appeared to be effective for many features of IBS, but its adverse effects, most notably constipation, limited its use. Since our study excluded individuals with concurrent major depression, it appears that duloxetine may benefit IBS independently of its antidepressant effects. These encouraging but preliminary open-label findings support further investigation of duloxetine treatment in placebo-controlled trials of IBS.

Methods

Results

Related Articles

The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: Results from three clinical trials
Journal of Anxiety Disorders, 11/13/09    Relevance Score: 66%

Fibromyalgia: The diagnosis and pharmacologic treatment
European Journal of Pain, 11/12/09    Relevance Score: 64%

Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia
International Journal of Clinical Rheumatology, 10/19/09    Relevance Score: 64%

Review: differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression
Evidence-Based Medicine, 10/26/09    Relevance Score: 63%

Tinnitus in postherpetic neuralgia
The Journal of Headache and Pain, 10/26/09    Relevance Score: 62%

Today in Clinical Pharmacology...keeping you current

Divalproex Sodium-Induced Eosinophilic Pleural Effusion
American Journal of Therapeutics, 12/04/09

Lithium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09

Acute Generalized Exanthematous Pustulosis: A Rare Clinical Entity With Use of Piperacillin/Tazobactam
American Journal of Therapeutics, 12/04/09